Get the Stockscreener App
1.72
2.38%
0.04
After Hours:
1.77
0.05
+2.91%
Black Diamond Therapeutics Inc stock is traded at $1.72, with a volume of 113.44M.
It is up +2.38% in the last 24 hours and down -27.43% over the past month.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
See More
Previous Close:
$1.68
Open:
$2.36
24h Volume:
113.44M
Relative Volume:
46.48
Market Cap:
$97.46M
Revenue:
-
Net Income/Loss:
$-82.44M
P/E Ratio:
-0.9149
EPS:
-1.88
Net Cash Flow:
$-66.75M
1W Performance:
-3.91%
1M Performance:
-27.43%
6M Performance:
-64.02%
1Y Performance:
-62.85%
1-Day Range:
$1.71
$2.78
1-Week Range:
$1.62
$2.78
52-Week Range:
$1.59
$7.66
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Name
Black Diamond Therapeutics Inc
Sector
Industry
Phone
617-417-5868
Address
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Compare BDTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
1.72 | 97.46M | 0 | -82.44M | -66.75M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-24 | Initiated | Raymond James | Outperform |
| Jul-14-23 | Initiated | Piper Sandler | Overweight |
| Jun-30-23 | Upgrade | Stifel | Hold → Buy |
| Jun-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-29-22 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-22-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jan-07-21 | Initiated | Wedbush | Outperform |
| Nov-24-20 | Initiated | Berenberg | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | Canaccord Genuity | Buy |
| Feb-24-20 | Initiated | Cowen | Outperform |
| Feb-24-20 | Initiated | JP Morgan | Overweight |
| Feb-24-20 | Initiated | Jefferies | Buy |
View All
Black Diamond Therapeutics Inc Stock (BDTX) Latest News
Black Diamond Gets The Gift Of Time In License Pact With Servier - Citeline News & Insights
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, a Targeted Oncology Therapy - Marketscreener.com
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High - MSN
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Yea - Asianet Newsable
Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million - Benzinga
Black Diamond Therapeutics (BDTX) Stock Jumps After Entering Licensing Deal - Stocks Telegraph
Black Diamond stock surges on licensing deal (BDTX:NASDAQ) - Seeking Alpha
Servier and Black Diamond collaborate on BDTX-4933 - The Pharma Letter
Black Diamond Therapeutics, Servier Sign Global Licensing Deal for BDTX-4933 to Treat Solid Tumors - Marketscreener.com
Black Diamond rises on licensing deal for tumor treatment - TradingView
Black Diamond stock soars on licensing deal By Investing.com - Investing.com Australia
Servier And Black Diamond Therapeutics Announce Global Licensing Agreement For BDTX-4933, A Targeted Oncology Therapy - Marketscreener.com
Servier and Black Diamond enter oncology licensing deal - Investing.com
Servier and Black Diamond enter oncology licensing deal By Investing.com - Investing.com UK
Servier and Black Diamond Therapeutics Announce Global - GlobeNewswire
$780M Cancer Drug Deal: Servier Acquires Rights to Black Diamond's Promising RAS/RAF Inhibitor - StockTitan
HC Wainwright Issues Positive Forecast for Black Diamond Therapeutics (NASDAQ:BDTX) Stock Price - Defense World
Black Diamond Therapeutics Reports 2024 Financial Results - MSN
Black Diamond Therapeutics: In Decline, But Why? (NASDAQ:BDTX) - Seeking Alpha
Rhumbline Advisers Has $120,000 Holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
BDTX stock touches 52-week low at $1.76 amid market challenges - Investing.com Australia
BDTX stock touches 52-week low at $1.76 amid market challenges By Investing.com - Investing.com South Africa
Black Diamond Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Brokers Issue Forecasts for BDTX Q1 Earnings - Defense World
Stifel Nicolaus Lowers Black Diamond Therapeutics (NASDAQ:BDTX) Price Target to $15.00 - Defense World
Wedbush Reiterates Outperform Rating for Black Diamond Therapeutics (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
Wedbush Adjusts Black Diamond Therapeutics Price Target to $11 From $16, Maintains Outperform Rating - Marketscreener.com
Black Diamond: Q4 Earnings Snapshot - Midland Daily News
Black Diamond Therapeutics Q4 Loss Decreases, Beats Estimates - Nasdaq
Black Diamond Therapeutics Reports Fourth Quarter and Full - GlobeNewswire
BDTX stock touches 52-week low at $1.91 amid market challenges By Investing.com - Investing.com South Africa
BDTX stock touches 52-week low at $1.91 amid market challenges - Investing.com Australia
Black Diamond Financial LLC Acquires New Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Update - MarketBeat
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Significant Decline in Short Interest - Defense World
NAYA Biosciences Announces Nomination of New Board Members - The Manila Times
February 2025 US Penny Stocks With Promising Prospects - Simply Wall St
SG Americas Securities LLC Makes New $42,000 Investment in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics Inc (BDTX) Stock: A Year of Market Fluctuations - The InvestChronicle
PL’s Stock Market Adventure: 60.64% YTD Growth Amidst Volatility - The InvestChronicle
Cemex S.A.B. De C.V. ADR’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
Black Diamond Therapeutics Inc (BDTX) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Axcelis Technologies Inc (ACLS) Shares Down Despite Recent Market Volatility - The News Heater
Analyzing the Price-to-Earnings Ratio of Black Diamond Therapeutics Inc (BDTX) - The News Heater
Molina Healthcare Inc’s Banking’s 100-Day Moving Average at 311.64: Will the Stock Break Through? - The InvestChronicle
Analyzing the Price-to-Earnings Ratio of Smithfield Foods, Inc (SFD) - The News Heater
CPAY Stock Sees Surge of Approximately 1.95% in Last Five Days - Knox Daily
Black Diamond Therapeutics Inc [BDTX] Records 200-Day SMA of $4.25 - Knox Daily
CVRx Inc [CVRX] Shares Fall -7.20 % on Wednesday - Knox Daily
Post Holdings Inc [POST] Shares Jump Approximately 3.76% Over the Year - Knox Daily
Black Diamond Therapeutics Inc Stock (BDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):